Related Experiment Video

Updated: Aug 14, 2025

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

250

Metabolic effects of L-citrulline in type 2 diabetes

Fatemeh Bagheripour1, Sajad Jeddi1, Khosrow Kashfi2

  • 1Endocrine Physiology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Acta Physiologica (Oxford, England)
|January 16, 2023
PubMed

Insights

L-citrulline (Cit) supplementation may help manage type 2 diabetes (T2D). Studies show Cit improves blood sugar, lipids, and insulin function, offering potential as a novel T2D therapeutic.

Area of Science:

  • Metabolic disease research
  • Nutritional science
  • Pharmacology

Background:

  • Type 2 diabetes (T2D) prevalence is rising globally.
  • Reduced nitric oxide (NO) bioavailability contributes to T2D pathophysiology.
  • L-citrulline (Cit) is an NO precursor with potential therapeutic benefits for T2D.

Purpose of the Study:

  • To review human and animal studies on L-citrulline's effects on metabolic parameters in T2D.
  • To explore the mechanisms behind Cit's beneficial effects in T2D management.

Main Methods:

  • Systematic review of existing human and animal research.
  • Analysis of studies investigating Cit supplementation in T2D models.
  • Examination of biochemical and physiological markers related to T2D metabolism.

Main Results:

  • Cit supplementation increases circulating L-citrulline and L-arginine levels.
  • Cit reduces circulating glucose and free fatty acids, improving dyslipidemia.
  • Mechanisms include enhanced insulin secretion, increased glucose uptake, and altered fat metabolism.

Conclusions:

  • L-citrulline demonstrates antihyperglycemic, antidyslipidemic, and antioxidant effects in T2D.
  • Cit influences pancreatic beta-cell function, skeletal muscle glucose uptake, and adipose tissue metabolism.
  • L-citrulline shows promise as a novel therapeutic agent for managing type 2 diabetes.
Keywords:
L-citrullinecarbohydrate metabolismnitric oxidepancreatic β cellskeletal muscletype 2 diabetes

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

713
Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice08:01

Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice

Published on: May 16, 2021

5.9K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
256
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
383
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.4K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
634
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
230